ES2156852T3 - Citoquina mamifera, il-11. - Google Patents

Citoquina mamifera, il-11.

Info

Publication number
ES2156852T3
ES2156852T3 ES90917548T ES90917548T ES2156852T3 ES 2156852 T3 ES2156852 T3 ES 2156852T3 ES 90917548 T ES90917548 T ES 90917548T ES 90917548 T ES90917548 T ES 90917548T ES 2156852 T3 ES2156852 T3 ES 2156852T3
Authority
ES
Spain
Prior art keywords
mamifera
citoquina
cells involved
stimulating
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917548T
Other languages
English (en)
Inventor
Yu-Chung Yang
Frances K Bennett
R Paul Stephen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Genetics Institute LLC
Original Assignee
Childrens Medical Center Corp
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp, Genetics Institute LLC filed Critical Childrens Medical Center Corp
Application granted granted Critical
Publication of ES2156852T3 publication Critical patent/ES2156852T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE PRESENTAN UNA NUEVA CITOQUINA MAMIFERA, LA IL-II, Y UN PROCESO PARA SU PRODUCCION. LA IL-II SE PUEDE UTILIZAR EN PREPARACIONES FARMACEUTICAS PARA ESTIMULAR Y/O REFORZAR LAS CELULAS QUE TIENE QUE VER CON LA RESPUESTA INMUNE Y LAS CELULAS QUE TIENE QUE VER CON EL CORRECTO FUNCIONAMIENTO DEL SISTEMA HEMATOPOYETICO.
ES90917548T 1989-11-22 1990-11-20 Citoquina mamifera, il-11. Expired - Lifetime ES2156852T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44110089A 1989-11-22 1989-11-22
US07/526,474 US5215895A (en) 1989-11-22 1990-05-21 Dna encoding a mammalian cytokine, interleukin-11

Publications (1)

Publication Number Publication Date
ES2156852T3 true ES2156852T3 (es) 2001-08-01

Family

ID=27032674

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917548T Expired - Lifetime ES2156852T3 (es) 1989-11-22 1990-11-20 Citoquina mamifera, il-11.

Country Status (13)

Country Link
US (4) US5215895A (es)
EP (1) EP0504177B1 (es)
JP (2) JP2688539B2 (es)
KR (1) KR970005050B1 (es)
AT (1) ATE199096T1 (es)
CA (1) CA2069428C (es)
DE (1) DE69033700T2 (es)
DK (2) DK0504177T3 (es)
ES (1) ES2156852T3 (es)
GR (1) GR3035627T3 (es)
HU (1) HU215233B (es)
MX (1) MX9203439A (es)
WO (1) WO1991007495A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
JP2752819B2 (ja) * 1990-11-08 1998-05-18 三共株式会社 新規サイトカイン
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5460810A (en) * 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
SK166695A3 (en) * 1994-03-31 1997-02-05 Amgen Inc Mgdf polypeptide for stimulating growth and megakaryocyte differentiation
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
US6274547B1 (en) * 1996-06-14 2001-08-14 Genetics Institute, Inc. Methods comprising the use of human interleukin-11 receptor proteins
DK0797664T3 (da) 1994-12-22 2007-01-22 Genetics Inst Llc Anvendelse af en human interleukin-11-receptor
US5760189A (en) * 1995-06-02 1998-06-02 Genetics Institute, Inc. Protein recovery & purification methods
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
EP0833656A4 (en) * 1995-06-09 1999-02-03 Yeda Res & Dev RESTRICTINE P / ACTIVINE A CONTAINING PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS IL-6 OR / AND IL-11 ANTAGONISTS
US6887461B1 (en) 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US5686246A (en) * 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
KR100426286B1 (ko) * 1996-01-09 2004-06-30 주식회사 엘지생명과학 효모를이용한인간인터루킨-11의제조방법
AUPO439396A0 (en) 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
AU764292B2 (en) * 1998-01-23 2003-08-14 Genetics Institute, Llc Method of using IL-11 to enhance cell mediated immunity for treating various viral and parasitic infections and cancer
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6265165B1 (en) * 1998-11-12 2001-07-24 The Regents Of The University Of California Methods for EST-specific full length cDNA cloning
US6953777B2 (en) * 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
AU3738300A (en) * 1999-03-11 2000-09-28 Genetics Institute Inc. Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2001007076A1 (en) * 1999-04-15 2001-02-01 Genetics Institute, Inc. Use of interleukin-11 to treat gastrointestinal disorders
US6274135B1 (en) * 1999-06-22 2001-08-14 Genetics Institute, Inc. Method of using IL-11 for inflammation associated with acute pancreatitis
MXPA02000525A (es) * 1999-07-15 2005-07-01 Inst Genetics Llc Formulaciones de il-11.
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
CA2498931A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
ES2282904T3 (es) 2003-09-12 2007-10-16 Wyeth Barras solidas de fosfato calcico inyectables para el suministro de proteinas osteogenicas.
WO2005085283A1 (ja) * 2004-03-03 2005-09-15 Yamanouchi Pharmaceutical Co., Ltd. 修飾インターロイキン−１１及びそれを含有する医薬組成物
WO2006081379A1 (en) * 2005-01-26 2006-08-03 Wyeth Use of sfrps as markers of bmp activity
US20070160577A1 (en) * 2005-12-06 2007-07-12 Wyeth Interleukin-11 compositions and methods of use
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
WO2011151716A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9320777B2 (en) 2011-05-13 2016-04-26 Bolder Biotechnology, Inc. Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11229683B2 (en) 2015-09-18 2022-01-25 Bolder Biotechnology, Inc. Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
WO2018132787A1 (en) 2017-01-16 2018-07-19 Nansha Biologics (Hk) Limited Systems and methods for production of recombinant il-11 in yeast
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5371193A (en) * 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
JPH0571866A (ja) * 1991-09-17 1993-03-23 Matsushita Refrig Co Ltd 断熱箱体

Also Published As

Publication number Publication date
KR920703819A (ko) 1992-12-18
HU215233B (hu) 1998-11-30
HU9201712D0 (en) 1992-09-28
ATE199096T1 (de) 2001-02-15
DK66692D0 (da) 1992-05-21
GR3035627T3 (en) 2001-06-29
DK66692A (da) 1992-07-22
US5215895A (en) 1993-06-01
JPH104982A (ja) 1998-01-13
AU6757890A (en) 1991-06-13
DE69033700D1 (de) 2001-03-15
EP0504177A1 (en) 1992-09-23
JP2688539B2 (ja) 1997-12-10
US5854028A (en) 1998-12-29
JP2783361B2 (ja) 1998-08-06
HUT64595A (en) 1994-01-28
AU644389B2 (en) 1993-12-09
JPH05504560A (ja) 1993-07-15
US5700664A (en) 1997-12-23
CA2069428A1 (en) 1991-05-23
EP0504177B1 (en) 2001-02-07
DK0504177T3 (da) 2001-04-02
DE69033700T2 (de) 2001-09-13
KR970005050B1 (ko) 1997-04-11
MX9203439A (es) 1992-08-01
US6066317A (en) 2000-05-23
CA2069428C (en) 2001-07-31
WO1991007495A1 (en) 1991-05-30

Similar Documents

Publication Publication Date Title
ES2156852T3 (es) Citoquina mamifera, il-11.
ES8606289A1 (es) Un procedimiento para la preparacion de piridazinaminas.
MY102472A (en) Preparation of funtional human urokinase proteins.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
HK166495A (en) HIV-1 envelope muteins lacking hypervariable domains
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
DE3061854D1 (en) Process for the preparation of interferon and culture medium composition used in it
NO922456D0 (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
DE3585049D1 (de) Monoklonale antikoerper.
ATE84221T1 (de) Arzneimittel mit methylcellulose.
FI880636A0 (fi) Foerfarande foer inaktivering av med hoelje foersedda virus i en medelst en cell in vitro framstaellda proteinprodukter.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa
ES2056872T3 (es) Proteina pp4-x anticoagulante, su preparacion y empleo.
DE3675631D1 (de) In-vitro-kulturverfahren.
ATE100312T1 (de) Einkristalle von -g(b)-phenylpropiophenonen.
IT1053845B (it) Procedimento per l arricchimento di prodotti agricoli in proteine e vitamine
ES8300475A1 (es) Un procedimiento para la preparacion de un alergeno
DK222988D0 (da) Farmaceutiske praeparater indeholdende ornithin-decarboxylase-inhibitorer
IT8820916A0 (it) Procedimento ed impianto per la coltura di microorganismi.
NO874391L (no) Nye gjaerekspresjonsvektorer for ifn-omega samt fremgangsmaate for fremstilling og anvendelse derav.
IT1233453B (it) Produzione di vincamina e di epivincamina mediante colture di cellule di vinca minor.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504177

Country of ref document: ES